FDA Debarment List

Maria Anzures-Camarena Permanent Debarment - FDA Drug Applications

FDA issued a permanent debarment order for Maria Anzures-Camarena, prohibiting her from submitting or assisting in the preparation of drug applications to the agency. The debarment stems from her felony conviction related to drug application matters. All FDA-regulated drug product applications submitted by or on behalf of Ms. Anzures-Camarena are permanently barred.

Permanent Debarment Order - Miguel Angel Montalvo Villa

The FDA issued a Final Debarment Order permanently excluding Miguel Angel Montalvo Villa from submitting or providing assistance in the preparation of drug applications under section 306(a) or (b) of the FD&C Act. The debarment follows a conviction under federal law related to drug product approval. This action prohibits Montalvo Villa from any role in drug application submissions to FDA.

FDA Permanent Debarment Order - John Warrington Kosolcharoen

FDA issued a final permanent debarment order against John Warrington Kosolcharoen, barring him from participating in any way in the submission of applications for FDA approval or accreditation. The debarment relates to activities concerning FDA-regulated products, specifically applications under the Federal Food, Drug, and Cosmetic Act.

Bernardo Garmendia Permanent Debarment Order

The FDA issued a permanent debarment order against Bernardo Garmendia, preventing him from providing services in any capacity related to drug marketing or distribution under the FD&C Act. The order, effective March 14, 2025, follows Garmendia's felony conviction for a drug-related offense, denying his request for a hearing. Pharmaceutical companies and clinical investigators must ensure no engagement with debarred parties.

Matthew Teltser Permanent Debarment Order

The FDA issued a final order permanently debarring Matthew Teltser from providing services to any person or entity that has an approved or pending drug application. The debarment prohibits Teltser from directly or indirectly participating in any FDA-regulated drug business activities. This enforcement action (Docket No. FDA-2025-N-1956) took effect on February 6, 2026.